US FDA approves first drug for fatty liver disease NASH

Health

Reuters was first to report^[1] on the FDA approving Madrigal Pharmaceuticals’ drug Rezdiffra, an oral drug to treat a fatty liver disease known as non-alcoholic steatohepatitis (NASH). The approval was the first of its kind. 

Market Impact

The

Read more https://www.reutersagency.com/en/reutersbest/article/us-fda-approves-first-drug-for-fatty-liver-disease-nash/